Tower Research Capital (TRC)’s Scinai Immunotherapeutics SCNI Stock Holding History

Tower Research Capital (TRC)’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12	Closed	-$2K	–	6469
2022 Q1	$2K	Buy	+12	New	+$1.74K	﹤0.01%	5591
2021 Q4	–	Sell	-1	Closed	–	–	6527
2021 Q3	$0	Buy	+1	New	+$257	﹤0.01%	6123
2017 Q2	–	Sell	-1	Closed	-$1K	–	3364
2017 Q1	$1K	Buy	+1	New	+$515	﹤0.01%	2839
2016 Q4	–	Sell	-5	Closed	-$2K	–	4328
2016 Q3	$2K	Buy	+5	New	+$1.82K	﹤0.01%	3127
2016 Q2	–	Sell	-8	Closed	-$3K	–	4903
2016 Q1	$3K	Buy	+8	New	+$2.95K	﹤0.01%	3158
2015 Q4	–	Hold	0	–	–	–	4988
2015 Q3	–	Sell	-13	Closed	-$5.31K	–	4660
2015 Q2	$6K	Buy	+13	New	+$6.12K	﹤0.01%	3141

Other funds holding SCNI

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

TPWA

TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Tower Research Capital (TRC)'s SCNI Position: Q2 2022 in Review

Tower Research Capital (TRC) sold out of Scinai Immunotherapeutics (SCNI) in Q2 2022, closing a stake of 12 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in SCNI in Q2 2015 and held it in 6 quarters. The position peaked at $6K in Q2 2015. 14 funds tracked by Wall St. Rank hold SCNI as of Q2 2022.

Tower Research Capital (TRC) reported no remaining Scinai Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 12 Scinai Immunotherapeutics shares in Q2 2022, an estimated $2K.
Tower Research Capital (TRC) first reported a position in Scinai Immunotherapeutics in Q2 2015 and held it in 6 quarters.
Tower Research Capital (TRC)'s Scinai Immunotherapeutics position peaked at $6K in Q2 2015.
14 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2022, filed 15 Aug 2022.